Vivos Therapeutics, Inc. (VVOS) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 4 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for VVOS is $2.25, representing a +66.7% upside from the current price of $1.35. Price targets range from a low of $2.25 to a high of $2.25.
